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Introduction
Despite reported falling transmission in much of sub-Saharan 
Africa,1–3 malaria remains a leading cause of inpatient admissions 
and mortality in paediatric wards.4–6 The policy for first-line 
treatment of severe malaria is a critical factor in determining 
malaria mortality. The choice of treatment must ultimately be 
dictated not only by its efficacy, but also by the ability of frail 
health systems to sustain its routine use. In much of sub-Saharan 
Africa, per-capita health expenditure remains extremely low, with 
annual government health expenditure per capita averaging 34 
United States dollars (US$).7 The cost of inpatient care for a case 
of severe malaria has been estimated at between US$ 12 and US$ 
75 and this poses a considerable burden on limited resources.4,8
Quinine remains the mainstay treatment of severe malaria 
in sub-Saharan Africa. Parenteral quinine costs as little as US$ 
0.27 per ampoule9,10 and is widely available in health facilities 
across the continent. It is administered either intramuscularly or 
intravenously, three times per day. As an infusion quinine must 
be given over several hours and although it is well absorbed when 
given intramuscularly, this route can cause abscesses and sciatic 
nerve damage and has been associated with tetanus.11 Artesunate 
is a more expensive drug, costing around US$ 1.06 per vial. 
However, it is only administered once daily and can be given as 
an intravenous bolus injection or by intramuscular injection. It 
has also been shown to be safe and well tolerated.12
Artesunate has previously been shown not only to be more 
effective for the treatment of severe malaria in adults in Asia, 
but also highly cost-effective, with a cost per death averted of 
just under US$ 150.10 Whether these findings are transferable 
to children in Africa, among whom the largest share of malaria 
mortality occurs, remains to be explored. The African Quinine 
Artesunate Malaria Treatment (AQUAMAT) trial is the largest 
hospital-based clinical trial for severe malaria to date.13 It was 
carried out in 11 sites in 9 countries across sub-Saharan Africa 
and recruited children with severe malaria who were random-
ized to receive either parenteral quinine or artesunate. Parenteral 
treatment was completed with a course of oral artemisinin com-
bination therapy. The primary outcome measure was in-hospital 
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Objective To explore the cost-effectiveness of parenteral artesunate for the treatment of severe malaria in children and its potential 
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mortality, with neurological disability 
assessed at 28 days as an important sec-
ondary outcome.
This economic analysis was con-
ducted alongside the AQUAMAT clini-
cal trial to explore the cost-effectiveness 
of artesunate for the management of 
severe malaria in children in sub-Saharan 
Africa. The budget impact of the use of 
artesunate was also estimated to assess its 
affordability in routine practice.
Methods
Evaluation framework
A provider perspective was taken, being 
most relevant to the context of inpatient 
care. This perspective accounts for all 
resources used in health facilities for 
the treatment of severe malaria as well 
as for mortality and disability among 
the patients. The evaluation framework 
is a cost-effectiveness analysis using cost 
per disability-adjusted life year (DALY) 
averted and cost per death averted as 
measures of cost-effectiveness.
When one drug is more expensive and 
more effective than its comparator, the 
incremental cost per DALY averted is cal-
culated. This ratio is compared with a deci-
sion threshold that is assumed to convey 
the maximum policy-makers are willing 
and able to pay for an additional DALY 
averted. The baseline decision thresholds 
used as a reference are the conservative 
estimates of US$ 25 and US$ 150, as sug-
gested by the World Health Organization 
(WHO) and the World Bank.14,15
Data collection
The study was conducted in four of the 11 
AQUAMAT sites.13 Two of the selected 
sites, Muheza and Korogwe, were in dif-
ferent areas of the United Republic of 
Tanzania. A third site was in Mbarara, 
Uganda, and a fourth in Ilorin, Nigeria. 
The sites were chosen to represent geo-
graphical and epidemiological diversity 
(Table 1). Medical resource use and cost 
data were collected between June 2009 
and July 2010, when the last patient was 
recruited. Treatments, diagnostic tests 
and medical equipment used in the man-
agement of severe malaria were recorded 
for a total of 2300 patients.
The hotel costs of inpatient care (i.e. 
costs of capital, supportive departments 
and labour) were obtained from WHO’s 
choosing interventions that are cost-effective 
(WHO-CHOICE) framework,16 which 
stratifies costs by country and health 
facility level. The cost per inpatient day 
was multiplied by the patient length of 
stay. Drug costs were obtained from the 
International drug price indicator guide 
using the median buyer price.9 Costs of 
laboratory tests were estimated using pa-
tient charges. All costs were calculated in 
US$ at 2009 prices; the WHO-CHOICE 
costs were obtained in 2005 local currency 
units, adjusted for inflation using the con-
sumer price index and converted to US$ 
using the official average 2009 exchange 
rate.17,18 Life-time costs associated with 
neurological sequelae were not included. 
Mortality and disability data were derived 
from the pooled estimates from all 11 sites 
in the AQUAMAT study.13
Model outline
A decision tree was constructed to depict 
the progression from severe illness treated 
with either artesunate or quinine (Fig. 1). 
Patients can enter either the quinine 
or artesunate arm, where they either 
survive or die according to the mortality 
observed in the trial. The number of life 
years lost (YLL) for patients that die are 
calculated according to the patient’s age 
and life expectancy at death. Surviving 
patients can either be cured or have mild, 
moderate or severe neurological sequelae. 
The years lived with disability (YLD) are 
calculated for patients with neurologi-
cal sequelae. The percentages shown in 
Fig. 1 are the baseline mean estimates 
for each chance node. The model draws 
random samples from the data set with 
replacement (bootstrapping) to derive 
the costs and from assigned distributions 
for probabilities at each branch. The costs 
associated with each treatment include 
those for the antimalarials and other 
drugs, supportive treatment, diagnostic 
tests, treatment of adverse events and 
hotel costs for inpatient stay.
The primary measure of clinical out-
come was the number of DALYs in each 
of the treatment arms. DALYs account 
for both YLL due to early mortality and 
YLD, calculated using standard meth-
ods.19 The number of YLL for a patient 
that died was dependent on the average 
patient age and life expectancy in the four 
countries where the data were collected. 
This value was discounted using a baseline 
value of 3% annually.20 Full age modula-
tion was included in the baseline analysis, 
implying more conservative effectiveness 
gains.19 Disability weights for patients 
with sequelae were based on their condi-
tion as documented on day 28 follow-up 
visits; disability weights were assigned 
using the Global Burden of Disease tables, 
as shown in Table 2.21 Disability during 
the illness episode was not included, as 
this was assumed to be minor and equal 
between treatment arms and therefore to 
Table 1. Sites included in the African Quinine Artesunate Malaria Treatment trial
Sitea Region of Africa Malaria endemicity Hospital level
Korogwe, United Republic of Tanzania Eastern Endemic and perennial with seasonal peaks/Low Primary (district hospital)
Teule, United Republic of Tanzania Eastern Endemic and perennial with seasonal peaks/High Secondary (district hospital)
Mbarara, Uganda Eastern/Central Endemic and perennial with seasonal peaks/High Tertiary
Ilorin, Nigeria Western Endemic and perennial with seasonal peaks/High Tertiary
Mozambique Southern Endemic and perennial with seasonal peaks/High Tertiary
Gambia Western Endemic with seasonal transmission/High Tertiary
Ghana Western Endemic and perennial with seasonal peaks/High Tertiary
Kenya Eastern Endemic and perennial with seasonal peaks/Low Secondary (district hospital)
Rwamagana, Rwanda Eastern Endemic and perennial with seasonal peaks/Low Secondary (district hospital)
Niyanza, Rwanda Eastern Endemic and perennial with seasonal peaks/Low Secondary (district hospital)
Democratic Republic of the Congo Central Endemic and perennial with seasonal peaks/High Secondary (district hospital)
a The top four sites were included in the costing analysis.
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have no effect on the incremental advan-
tage of either treatment.
The secondary measure of outcome 
was the incremental cost per death avert-
ed, calculated by multiplying the numbers 
needed to treat (NNT) to avert a death by 
the difference in treatment costs.
Sensitivity analyses
We used one-way sensitivity analyses for 
parameters whose estimates were not 
based on high-level evidence, or in cases 
in which the choice of parameter value 
was methodological. The discount rate 
varied between 0–10%, life expectancy 
was changed from local to global esti-
mates, and the use of age modulation for 
the calculation of DALYs was omitted.20 
We did a threshold analysis for the drug 
costs at which the decision to adopt one 
intervention over the other is reversed.
We did a probabilistic sensitivity 
analysis for parameter uncertainty in cost 
and for clinical outcomes. The analysis 
was done in TreeAge Pro® by running 
the model 50 000 times, each time ran-
domly selecting from the range of values 
for each parameter. For costs, the values 
were drawn from the database of patient 
Fig. 1. Dendrogram showing clinical progression
Severe Malaria
Quinine
Survive
NS
Mild
Moderate
Severe
7%
19%
74%
1.2%
Cured
98.8%
89.1%
Die
10.9%
Artesunate
Survive
NS
Mild
Moderate
Severe
23%
9%
68%
1.4%
Cured
98.6%
91.5%
Die
8.5%
NS, neurological sequelae.
Table 2. Disability weights, costs and analytical parameter values
Parameter Baseline estimate (distribution parameters or sensitivity 
analysis values)
Source
Mortality
Quinine (pooled) 0.109 (β distribution; α = 167; β = 1 357) Primary
Artesunate (pooled) 0.085 (β distribution; α  = 264; β = 2 847)
Neurological sequelae
Quinine (pooled) 0.012 (β distribution; α  = 21; β = 2 692) Primary
Artesunate (pooled) 0.014 (β distribution; α  = 22; β = 2 690)
Disability weighting
Mild neurological sequelaea 0.024 21
Moderate neurological sequelaeb 0.248 21
Severe neurological sequelae 0.471 21
Costs
Hotel (2009 US$ per day)
   Ilorin, Nigeria 18.9 16
   Mbarara, Uganda 7.7 16
   Muheza, United Republic of Tanzania 7.4 16
   Korogwe, United Republic of Tanzania 5.7 16
Quinine dihyrocholride (300 mg/ml, 2 ml ampoule) cost (US$) 0.27 9
Artesunate (60 mg vial, 1 ml ampoule) cost (US$) 1.06 9
Analytical values
Decision threshold (US$) 150 (25–880) 14,15
Annual discount value (%) 3 (0–10) 19
Age modulation 1 (0) 19
US$, United States dollar.
a Based on weighting for cognitive impairment following meningitis.
b Based on motor impairment following meningitis.
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costs. For clinical outcomes, β distribu-
tions were calculated from the incidence 
of mortality and neurological sequelae 
in surviving patients in all AQUAMAT 
study sites and were converted in the 
model to DALYs. The measure of disper-
sion reported for DALYs are the values 
for the interval between the 2.5% and 
97.5% percentiles, defined here as the 
95% percentile interval (95% PI).22
The incremental cost-effectiveness 
ratio was compared against a range of 
thresholds for policy-makers’ willingness 
to pay for the additional health benefit. 
This was summarized using cost-effec-
tiveness acceptability curves, indicating 
the probability that the intervention is 
cost-effective given the uncertainty sur-
rounding the model parameters across a 
range of willingness-to-pay thresholds.22
Budget impact analysis
The annual costs of treating all paediatric 
malaria admissions with artesunate rather 
than quinine over one year were calcu-
lated based on the cost of inpatient care 
multiplied by the annual number of severe 
malaria admissions in the four study sites. 
Costs were also calculated with the exclu-
sion of hotel costs (overheads and labour), 
which are not immediately affected by the 
choice of antimalarial drug treatment. 
The annual number of severe malaria 
admissions in each site was obtained from 
hospital records for 2008, apart from 
Korogwe, where these data were not 
available. For Korogwe the number of 
admissions in the AQUAMAT trial was 
used instead.
Ethical approval
Ethical approval for the AQUAMAT trial 
was obtained from the Oxford Tropical 
Research Ethics committee and from the 
ethical review board in each site individu-
ally. Further approval was granted for the 
retrospective collection of cost data from 
the patients medical files.
Results
In 5425 patients enrolled in the main 
trial, mortality in the quinine arm was 
10.9% compared with 8.5% in the 
artesunate arm – a 22.5% (95% CI: 
8.1–36.9%) reduction. The NNT with 
artesunate to avert a death was 41 (95% 
CI: 25–112). There was no significant 
difference in the rate of neurological 
sequelae between the two arms. Com-
bining the differences in rates of mortal-
ity and neurological sequelae between 
treatment arms, an additional 0.7 (95% 
PI: 0.2–1.3) DALYs per patient were 
averted with artesunate by comparison 
with quinine (Table 3).
The costs of treatment were very 
similar between the two arms, as shown 
in Table 4, with a mean of US$ 66.5 (95% 
CI: 63.7–69.2) in the artesunate arm and 
only US$ 3 less in the quinine arm, at US$ 
63.5 (95% CI: 61.7–65.2).
The hotel costs constituted ap-
proximately half the total cost and were 
significantly higher in Ilorin, a tertiary 
hospital, than in other hospitals. The 
mean number of hospitalization days was 
slightly lower in the quinine arm, partly 
resulting from higher mortality rates early 
after admission.
The average cost of a full treatment 
course of quinine, until the patient was 
able to take oral medication, was just over 
US$ 1.3 (95% CI: 1.25–1.34), compared 
with an average cost of US$ 3.3 (95% 
CI: 3.2–3.4) in patients treated with 
artesunate. Costs for intravenous fluids 
were slightly higher in the quinine arm, 
in part because quinine administered 
intravenously is given as an infusion, 
whereas artesunate is administered as a 
bolus injection.
Given these costs and outcomes, the 
incremental cost per DALY averted when 
using artesunate rather than quinine was 
US$ 3.8 and the incremental cost per 
death averted was US$ 123 ($95% CI: 
75–336). The results for individual study 
sites are shown in Table 5.
Sensitivity analysis
Results were not sensitive to the param-
eters used in converting YLL and YLD 
to DALYs. Whether no discounting was 
applied or with a 10% discount value; 
with either global or local life expectancy 
estimates; and with and without the age 
modulation, the incremental cost-effec-
tiveness ratio varied between US$ 2.9 and 
US$ 4.3 per DALY averted.
A threshold analysis determined that, 
assuming even a conservative willingness 
to pay of US$ 150 per DALY averted, 
artesunate could cost up to US$ 105 per 
full treatment course before it ceased to 
be cost-effective. Although parenteral 
quinine is cheap, it comprises only a small 
fraction of the total costs of inpatient 
care. Even if quinine were obtained at no 
cost, this would not reverse the direction 
of the cost-effectiveness results. Fig. 2 il-
lustrates the relatively tight distribution 
for total cost of care which clustered 
closely around the mean values and 
almost never approached the threshold 
value above which artesunate ceased to 
be cost-effective.
The probabilistic sensitivity analysis 
explored the uncertainty surrounding 
the cost and clinical outcomes observed 
in the trial. Fig. 3 shows the cost-effec-
tiveness acceptability curve. At the very 
outset, when policy-makers are assumed 
not to be willing to pay anything for 
further health gains, the probability that 
either treatment would be cost-effective 
is almost equal at 50%. If, however, 
policy-makers are willing to pay up to 
US$ 25 for an additional DALY averted 
(the lowest benchmark commonly used 
in economic evaluation in the context 
of low income countries), artesunate 
appears to be more cost-effective with 
a probability of almost 80%. This prob-
ability exceeds 95% as the willingness to 
pay increases to the next commonly used 
threshold of US$ 150.
Table 3. Mortality and incidence of moderate or severe neurological sequelae
Parameter Quinine Artesunate
Mortality 297/2713 (10.9%) 230/2712 (8.5%)
Severe neurological sequelae 21/2713 (0.8%) 22/2712 (0.8%)
DALYs 3 (95% PI: 2.4–4.6) 2.3 (95% PI: 1.9–2.6)a
Incremental DALYs averted with the use of artesunate – 0.7(95% PI: 0.2–1.3)a
Incremental number needed to treat (with artesunate) to avert 1 death – 41 (95% CI: 25–112)
CI, confidence interval; DALY, disability-adjusted life year; PI, percentile interval.
a The 95% PI represents the interval between the 2.5% and 97.5% percentiles.
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Budget impact
The predicted impact on the study hos-
pital annual budgets of switching from 
parenteral quinine to artesunate is mini-
mal, or even cost-saving (Table 6). Ac-
counting for direct expenditure on drugs 
and other medical equipment, the impact 
ranged from an annual cost-saving of ap-
proximately US$ 500 in Korogwe to just 
under US$ 4000 in Nigeria. If overhead 
costs for inpatient care are included, the 
additional expenditure per annum in the 
Nigerian centre is much higher – just over 
$16 000. This is due to the survival benefit 
conferred by artesunate and the high costs 
per inpatient day incurred in this tertiary 
teaching hospital.
Discussion
This analysis shows that the cost of 
averting malaria-related deaths in sub-
Saharan Africa by switching from 
quinine to artesunate was extremely 
low, with a mean value of US$ 123 per 
death averted. The results are similar to 
the incremental cost per death averted 
in adult Asian patients, which was esti-
mated as US$ 148. Similarly, the cost per 
DALY averted with artesunate was only 
US$ 3.8, far below any of the commonly 
used willingness-to-pay thresholds. The 
cost-effectiveness acceptability curve 
suggested that the probability of artesu-
nate being cost-effective is approximately 
50% without any additional investment, 
and exceeded 95% at a willingness to pay 
of US$ 150. This compares very favour-
ably with other interventions, such as 
the use of insecticide-treated nets, with 
a cost per death averted of US$ 254 to 
US$ 3437.23 In addition, provided the 
drug is available, the use of artesunate 
is relatively easy to implement in any 
hospital setting.
While cost-effectiveness is an infor-
mative criterion for policy-makers consid-
ering the adoption of a new intervention, 
affordability must also be demonstrated, 
particularly in the highly constrained 
health systems present in many sub-
Saharan African countries. The large 
number of malaria admissions implies 
that any change in treatment strategies 
could have a substantial impact on frail 
health systems. We have demonstrated 
that the use of artesunate is not only 
highly cost-effective but also entirely 
affordable, having a minimal impact on 
hospital budgets and in some instances 
being cost-saving. Even if the proportion 
of severe malaria cases reaching health 
facilities were to increase, this would most 
likely remain an affordable intervention.
Limitations
The analysis was carried out from the 
provider perspective, although inclu-
sion of household costs would have had 
either no impact or would have favoured 
artesunate further. A broader societal 
perspective might also have accounted 
for the possibility of artemisinin resis-
tance emerging following widespread use 
of artesunate.24 This was not considered 
a high priority, as parenteral artesunate 
is provided only to patients with severe 
illness – a small fraction of the total 
number of antimalarial treatments used 
every year. Furthermore, almost all pa-
tients treated for severe malaria receive 
an effective oral combination therapy 
following treatment with the parenteral 
drug, reducing the likelihood of the de-
velopment of resistance.25
We did not include the nursing time 
associated with administrating drugs. We 
also excluded the cost of consumables such 
as syringes, needles, cannulas and infusion 
sets because of the difficulty in collecting 
these reliably and their relatively low cost. 
Both these labour and consumables costs 
are likely to be marginally higher with 
quinine than artesunate, because quinine 
is given 3 times per day and as an infusion 
requires extra consumables and careful 
monitoring. Their inclusion would there-
fore further enhance the cost-effectiveness 
of artesunate. Reducing nursing time can 
improve the care for other patients and in 
the long run could have a potential impact 
on hospital budgets.
The costs of changing drug policy 
were excluded, but as a one-off cost spread 
over the expected lifetime of the policy 
change, the impact on the incremental 
cost-effectiveness ratio would be mini-
mal. In some instances patient charges 
were used as proxies for costs. In practice, 
charges may not reflect actual economic 
costs. This has no effect on the incremen-
tal cost-effectiveness ratio as these items, 
mostly laboratory tests, were equally 
distributed in the trial arms.
There were several methodological 
limitations. While the use of DALYs al-
lows for comparison of cost-effectiveness 
estimates for different health conditions 
and interventions, it is not without 
its limitations.19,26,27 The use of age 
modulation, discounting, and global 
life expectancies has been criticized. In T
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this analysis we chose to adopt those 
methods and values that would imply the 
most conservative results in terms of the 
cost-effectiveness of artesunate. All these 
parameters were tested in the sensitivity 
analysis and showed only a minor impact 
on the results.
There was some variation in health 
outcomes and costs between the differ-
ent sites, and therefore in their respective 
incremental cost-effectiveness ratios. 
The trial was powered to capture differ-
ences in effectiveness by pooling all sites. 
The main clinical analysis did, however, 
test for between-site heterogeneity and 
no significant variation was found. We 
therefore used the pooled estimate for 
clinical outcomes in our analysis. The 
main driver for the difference in costs was 
the overhead cost for inpatient stay, which 
was derived from the WHO-CHOICE 
framework rather than the primary cost-
ing of hospital overheads. Differences in 
overhead expenditure, however, are not 
as immediately affected by the choice of 
treatment as the variable expenditure on 
drugs and medical resources, and would 
materialize only when hospitals adjust 
their overhead expenditure to any changes 
in inpatient throughput.
Conclusion
With this analysis we show that arte-
sunate is effective, cost-effective and 
affordable, which stands as evidence to 
support its use in children with severe 
malaria in Africa.
The parenteral artesunate currently 
available on the market and used in this 
study does not yet have international drug 
regulatory authority registration, but 
WHO pre-qualification of the Chinese 
product was recently approved and the 
drug is licensed for use in many malaria-
endemic countries and can be purchased 
with funds from the Global Fund to 
Fight AIDS, Tuberculosis and Malaria. 
A new formulation may be registered 
in the near future28 and could be more 
expensive. However, this analysis has 
shown that even if the cost of artesunate 
were substantially higher, it would remain 
a cost-effective option. ■
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Table 6. Hospital admissions for severe malaria and impact on hospital budgets of switching from parenteral quinine to artesunate 
to treat severe malaria in childen
Paremeter United Republic of Tanzania Mbarara, 
Uganda
Ilorin, Ni-
geriaMuheza Korogwe
Patients admitted with severe malaria per year (No.) 555 169 584 708
Annual cost of switching to artesunate including hotel costs (US$)a 699 −271 526 16 142
Annual cost of switching to artesunate excluding hotel costs (US$) b 755 −509 876 3894
US$, United States dollar.
a Overhead costs for inpatient care as estimated in the WHO-CHOICE database.
b Only direct expenditure that will be affected by switching from quinine to artesunate.
صلخم
 ءارحصلا  بونج ةعقاولا  نادلبلا  في  ةميخو  ايرلابم ينباصلما  لافطلأا  ةجلاعلم  ًانقح  ةاطعلما  تانيوزيترلأل  ةفلكتلا  ءاقل  ةيلاعفلا
ايقيرفأ  في  ةيقيرفلأا
 جلاعل  ًانقح  ةاطعلما  تانيوزيترلأل  ةفلكتلا  ءاقل  ةيلاعفلا  فاشكتسا  ضرغلا
.تايفشتسلما تاينازيم لىع ينمضلا كلذ يرثأتو لافطلأا في ةميخولا ايرلالما
 ايرلابم ينباصلما لافطلأل ىفشتسلما في ةياعرلا فيلاكتل مييقت ىرُجأ ةقيرطلا
 ايرلالما جلاع ةبرجتل ةصصخم ًايقيرفأ ًاعقوم 11 نم عقاوم ةعبرأ في ةميخو
 ليجست ىرج دقو .لفط 5400 نم ثركأ لىع كلذو ،تانويزيترلأابو يننيكلاب
 2300 لىإ ةمدقلما ديرولاب ةاطعلما لئاوسلاو ،ةيلمعلما تارابتخلااو ،ةيودلأا
 ددم لوط لِجُس ماك ،اهنم مهجورخ ىتح ىفشتسلما لىإ مهلوخد ذنم ضيرم
 ةقباطم ىرجو .ىفشتسلما  في ةياعرلا  ةفلكت  باسحل ىفشتسلما  في ةماقلإا
 باسحل  رارق  جذونم  في  تلخدأو  ةعمجلما  ةيريسرلا  جئاتنلا  عم  تايطعلما
 ةفلكتلاو  اهبنجت  نكملما  زجعلا  ددم  باستحاب  ةححصم ةنس  لكل  ةفلكتلا
.اهبنجت نكملما ةافولا لباقم
 يتعومجم  في  ًاهباشم  ةميخولا  ايرلالما  جلاع  ةفلكت  طسوتم  ناك  جئاتنلا
 عارذ  في  )65.2-61.7  :95%  ةقثلا  ةلصاف(  كييرمأ  رلاود  63.5  :ةساردلا
 عارذ  في  )69.2-63.7  :95%  ةقثلا  ةلصاف(  كييرمأ  رلاود  66.5  و  ،يننيكلا
 رادقبم لقأ تانويزيترلأاب ينجلاعلما لافطلأا تايفو لدعم ناكو .تانويزيترلأا
 ليباقعلل ةبسنلاب هسفن وه لدعلما ناكو ،يننيكلاب اوجلوع نبم ةنراقم 22.5%
 ددم باستحاب ةحصصلما رمعلا تاونس نم 2.3 :تانويزيترلأا عارذ( :ةيبصعلا
 باستحاب ةححصلما رمعلا تاونس نم 3.0 :يننيكلا عارذو ؛ضيرم لكل زجعلا
 ترهظأ  ،يدعاق  ىوتسمك  يننيكلا  عم  ةنراقلمابو  .)ضيرم  لكل  زجعلا  ددم
 نكيم زجعلا ددم باستحاب ةححصم ةنس لكل ةفلكتلا في ةدايز تانويزيترلأا
 رلاود  3.8  رادقبم  اهبنجت  نكيم  ةافو  لك  لباقم  ةفلكتلا  في  ةدايزو  اهبنجت
.لياوتلا لىع كييرمأ رلاود 123 و كييرمأ
 يننيكلل ًاروسيم ًلايدبو ةفلكتلا ءاقل ةياغلل ةلاعف تانويزيترلأا دعت جاتنتسلاا
 مادختسلا  ةيلالما  تاعبتلا  دعتو  .ةميخو  ايرلابم  ينباصلما  لافطلأا  ةجلاعلم
.ةيمهلأا ةيمدع ىفشتسلما لخاد ةياعرلا في ًاينيتور تانويزيترلأا
摘要 
撒哈拉以南非洲地区运用注射青蒿琥酯治疗患有重症疟疾儿童的成本效益
目的 旨在探讨运用注射青蒿琥酯治疗患有重症疟疾儿童的
成本效益以及该疗法对医院预算的潜在影响。
方法 非洲奎宁青蒿琥酯疟疾治疗试验涉及11个地点的
5400多名儿童,本文评估了其中四个地点患有重症疟疾儿
童的住院治疗成本。对2300名病人从住院到出院间的用
药、化验和静脉注射液均进行了记录,同时还记录了住院
天数以计算住院治疗成本。数据与所合并的临床结果相匹
配并输入决策模型用以计算所避免的每个残疾调整生命年
(DALY)的成本以及所避免的每例死亡的成本。
结果 两组研究小组中,治疗重症疟疾病人的平均成本类似:
奎宁手臂注射为63.5美元(95%可信区间,CI: 61.7-65.2),青
蒿琥酯手臂注射为66.5美元(95%可信区间,CI:63.7-69.2)
。接受青蒿琥酯治疗儿童的死亡率比接受奎宁治疗儿童的
死亡率低22.5%,而两种治疗方法的神经学后遗症相同(青蒿
琥酯手臂注射:每病患2.3残疾调整生命年;奎宁手臂注射:每
病患3.0残疾调整生命年)。与奎宁作为基线的情况相比,青
蒿琥酯显示所避免的每一残疾调整生命年的增量成本和所
避免的每例死亡的增量成本分别为3.8美元和123美元。
结论 青蒿琥酯是一种具有很高成本效益并且实惠的替代治
疗重症疟疾儿童奎宁疗法的另类疗法。采用青蒿琥酯作为
医院常规疗法的财政预算影响可以忽略。
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Résumé
Rentabilité de l’artésunate parentéral administré chez les enfants gravement atteints de paludisme en Afrique 
subsaharienne
Objectif Étudier la rentabilité de l’artésunate parentéral dans le cadre 
du traitement d’enfants gravement atteints de paludisme et son impact 
potentiel sur les budgets hospitaliers.
Méthodes Les coûts des soins administrés aux patients hospitalisés 
gravement atteints de paludisme ont été évalués dans 4 des 11 sites 
participant à l’essai Traitement quinine/artésunate contre le paludisme 
en Afrique, réalisé sur plus de 5400 enfants. Afin de calculer le coût de 
l’hospitalisation, les médicaments, les essais en laboratoire et les liquides 
intraveineux administrés à 2300 patients entre leur admission et leur sortie 
ont été enregistrés, ainsi que la durée de l’hospitalisation. Les données 
ont été comparées avec les résultats cliniques regroupés et intégrés à 
un modèle de décision afin de calculer le coût par année de vie corrigée 
du facteur invalidité (AVCI) évité et le coût par décès évité.
Résultats Le coût moyen du traitement des patients gravement atteints 
du paludisme s’est révélé similaire dans les deux groupes expérimentaux: 
63,5 dollars américains (US$) (intervalle de confiance 95% IC: 61,7–65,2) 
pour le bras recevant la quinine et 66,5 US$ (95% IC: 63,7–69,2) pour le 
bras recevant l’artésunate. Les enfants traités par artésunate affichaient 
un taux de mortalité inférieur de 22,5% à ceux recevant de la quinine, et 
un taux de séquelles neurologiques identique: (bras recevant l’artésunate: 
2,3 AVCI par patient; bras recevant la quinine: 3,0 AVCI par patient). En 
comparaison avec la quinine en tant que ligne de base, l’artésunate a 
démontré un coût incrémental par AVCI évitée et un coût incrémental par 
décès évité de 3,8 US$ et 123 US$, respectivement.
Conclusion Dans le cadre du traitement des enfants gravement atteints 
de paludisme, l’artésunate constitue une alternative extrêmement rentable 
et abordable par rapport à la quinine. Les implications budgétaires liées 
à l’adoption de l’artésunate pour une utilisation habituelle lors des soins 
hospitaliers sont négligeables.
Резюме
Соотношение «затраты – эффективность» при парантеральном применении артесуната для 
лечения детей с тяжелой формой малярии в странах Африки к югу от Сахары
Цель Исследовать соотношение «затраты – эффективность» 
при парентеральном применении артесуната для лечения 
тяжелой формы малярии у детей, а также оценить его 
потенциальное влияние на бюджет больницы.
Методы Затраты на оказание стационарной медицинской 
помощи детям с тяжелой формой малярии оценивалось в 
четырех из 11 медицинских учреждений, включенных в 
«Сравнительное исследование эффективности применения 
хинина и артесуната при лечении малярии в странах 
Африки», которое охватывало свыше 5400 детей. Для 
расчета стоимости стационарной помощи фиксировались 
расход лекарств, лабораторные анализы и расход жидкостей 
для внутривенного введения по 2300 пациентам за период 
от назначения до отмены, а также продолжительность 
пребывания в стационаре. Данные увязывались с 
совокупными клиническими исходами и вводились в 
модель принятия решений для расчета затрат на один 
предотвращенный DALY и на один предотвращенный 
смертельный исход.
Результаты Средняя стоимость лечения больных с тяжелой 
формой малярии была аналогичной в обеих испытуемых 
группах: 63,5 долл. США (95% доверительный интервал, 
ДИ: 61,7–65,2) в группе хинина, и 66,5 долл. США (95% ДИ: 
63,7–69,2) в группе артесуната. У детей, которых лечили 
артесунатом, смертность была на 22,5% ниже, чем у тех, кого 
лечили хинином, и отмечался тот же, чем у них, показатель 
неврологических осложнений: (группа артесуната: 2,3 DALY 
на 1 больного; группа хинина: 3,0 DALY на 1 больного). По 
сравнению с хинином как базовым уровнем, при лечении 
артесунатомпредельные затраты на 1 предотвращенный 
DALY и на 1 предотвращенный смертельный исход 
составляли 3,8 долл. США и 123 долл. США, соответственно.
Вывод Артесунат является высокоэффективным с точки 
зрения затрат и экономически доступным альтернативным 
лекарственным средством при лечении детей с тяжелой 
формой малярии. Бюджетные последствия применения 
артесуната для рутинного использования при оказании 
медицинской помощи в условиях больницы крайне 
незначительны.
Resumen
Relación coste-eficacia del artesunato para el tratamiento de niños con malaria grave en el África 
subsahariana
Objetivo Analizar la relación coste-eficacia del artesunato parenteral en 
el tratamiento de la malaria grave infantil y su posible impacto en los 
presupuestos hospitalarios.
Métodos En cuatro de los 11 centros incluidos en el Estudio 
comparativo de los tratamientos de la malaria con artesunato y quinina 
en África participaron más de 5400 niños. Para calcular el coste de 
la hospitalización se registraron los fármacos, las pruebas clínicas 
y los líquidos endovenosos suministrados a 2300 pacientes, desde 
su ingreso hasta el alta, según la duración del ingreso del paciente. 
Los datos se compararon con los resultados clínicos agrupados e 
introducidos en un modelo de decisión para calcular el coste por 
año de vida ajustada por discapacidad (AVAD) evitada y el coste por 
muerte evitada.
Resultados El coste medio del tratamiento de los pacientes con 
malaria grave fue similar en los dos grupos del estudio: 63,5 dólares 
estadounidenses (US$) (intervalo de confianza del 95%, IC: 61,7–
65,2) en el grupo de quinina y US$ 66,5 (IC del 95%: 63,7–69,2) 
en el grupo de artesunato. Los niños tratados con artesunato 
presentaron una mortalidad un 22,5% inferior que los tratados 
con quinina y la misma tasa de secuelas neurológicas: (grupo de 
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artesunato: 2,3 AVAD por paciente; grupo de quinina: 3,0 AVAD 
por paciente). En comparación con la quinina como referencia, el 
artesunato ha mostrado un coste incremental por AVAD evitado y 
un coste incremental por muerte evitada de US$ 3,8 y US$ 123, 
respectivamente.
Conclusión El artesunato es una alternativa a la quinina muy rentable y 
con una excelente relación coste-eficacia para el tratamiento de niños 
con malaria grave. Las implicaciones presupuestarias de la adopción 
del artesunato para su uso sistemático en la asistencia hospitalaria son 
insignificantes.
